Phase III
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Polyphor announced the decision to temporarily halt enrollment for the pivotal Phase III trials PRISM-MDR and PRISM-UDR evaluating murepavadin in patients with nosocomial pneumonia due to higher than expected acute kidney injury incidences in the murepavadin arm of the PRISM-MDR trial.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
The company announced today that the drug failed to meet its primary endpoint in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM), a type of brain cancer.
Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.
Full data will be shared at a later conference, but the study marked the first time a BTK inhibitor showed benefit as a monotherapy in CLL.
GW Pharmaceuticals anticipates filing a supplemental New Drug Application with the FDA for the new indication later this year.
The company announced today that it had positive results in a Phase III clinical trial evaluating the drug for insomnia in patients with mild-to-moderate Alzheimer’s disease dementia.
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.
PRESS RELEASES